Stratagen Quantitative Prostate MRI Platform Pilot Study
Interventistico
Fase non elencata
Urology Clinic at Sawgrass
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.
* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters?
Participants will:
- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Categoria di Trattamento
Dispositivo
Mutazioni richieste
Nessuno
Studio Iniziato
2025-09-24
Ultimo Aggiornamento dello Sponsor
2025-10-21
Completamento Stimato
2025-11-30
Idoneità
Criteri di Inclusione
* Subject has a prostate that would be considered for biopsy
* Age 40-90 years
* PSA ≥ 2.5
* Subject has been informed of the nature of the study and has provided written informed consent
Criteri di Esclusione
* Contraindication for MRI
* Prostate biopsy within the previous 12 weeks
* Implant in the pelvis that may cause artifact on MRI (e.g. hip replacement)
* History of prostatectomy or other local prostate cancer therapy (e.g., cryotherapy or brachytherapy), or previous pelvic irradiation
* Currently enrolled in another investigational drug or device study that clinically interferes with this study
* Unable to comply with the study requirements or follow up schedule
* Any condition the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject
Pensi che questo studio appaia erroneamente?
Dettagli del Disegno
AllocazioneN/A
Modello di InterventoSingle Group Assignment
MascheramentoNone (Open Label)
Numero da Arruolare45
Bracci e Interventi
Bracci
Interventi
Tipo: Experimental
Descrizione:
Interventi:
MRI
Misure di Esito
Misure di Esito Primarie
Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelinesBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
All serious adverse events attributable to the Stratagen Quantitative Prostate MRI Platform will be reported.
• Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjectsBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
Misure di Esito Secondarie
Nessuno
Interessato a partecipare?
Scopri di più su questo studio e se potresti essere idoneo a partecipare.
Aggiungi studio ai preferiti
Condividi Studio via Email
Scarica lo studio
Pensi che questo studio appaia erroneamente?
Segnala Studio
Scarica lo studio
Siti dello Studio
Questo studio ha 1 sito
Urology Clinic at Sawgrass Rochester, New York, US